Suppr超能文献

曲美他嗪对离体急性心力衰竭糖尿病小鼠心脏的治疗作用

Trimetazidine therapy for diabetic mouse hearts subjected to ex vivo acute heart failure.

作者信息

Breedt Emilene, Lacerda Lydia, Essop M Faadiel

机构信息

Cardio-Metabolic Research Group (CMRG), Department of Physiological Sciences, Stellenbosch University, Stellenbosch, South Africa.

出版信息

PLoS One. 2017 Jun 20;12(6):e0179509. doi: 10.1371/journal.pone.0179509. eCollection 2017.

Abstract

Acute heart failure (AHF) is the most common primary diagnosis for hospitalized heart diseases in Africa. As increased fatty acid β-oxidation (FAO) during heart failure triggers detrimental effects on the myocardium, we hypothesized that trimetazidine (TMZ) (partial FAO inhibitor) offers cardioprotection under normal and obese-related diabetic conditions. Hearts were isolated from 12-14-week-old obese male and female diabetic (db/db) mice versus lean non-diabetic littermates (db/+) controls. The Langendorff retrograde isolated heart perfusion system was employed to establish an ex vivo AHF model: a) Stabilization phase-Krebs Henseleit buffer (10 mM glucose) at 100 mmHg (25 min); b) Critical Acute Heart Failure (CAHF) phase-(1.2 mM palmitic acid, 2.5 mM glucose) at 20 mmHg (25 min); and c) Recovery Acute Heart Failure phase (RAHF)-(1.2 mM palmitic acid, 10 mM glucose) at 100 mmHg (25 min). Treated groups received 5 μM TMZ in the perfusate during either the CAHF or RAHF stage for the full duration of each respective phase. Both lean and obese males benefited from TMZ treatment administered during the RAHF phase. Sex differences were observed only in lean groups where the phases of the estrous cycle influenced therapy; only the lean follicular female group responded to TMZ treatment during the CAHF phase. Lean luteal females rather displayed an inherent cardioprotection (without treatments) that was lost with obesity. However, TMZ treatment initiated during RAHF was beneficial for obese luteal females. TMZ treatment triggered significant recovery for male and obese female hearts when administered during RAHF. There were no differences between lean and obese male hearts, while lean females displayed a functional recovery advantage over lean males. Thus TMZ emerges as a worthy therapeutic target to consider for AHF treatment in normal and obese-diabetic individuals (for both sexes), but only when administered during the recovery phase and not during the very acute stages.

摘要

急性心力衰竭(AHF)是非洲住院心脏病患者最常见的主要诊断疾病。由于心力衰竭期间脂肪酸β氧化(FAO)增加会对心肌产生有害影响,我们推测曲美他嗪(TMZ)(部分FAO抑制剂)在正常和肥胖相关糖尿病条件下具有心脏保护作用。从12 - 14周龄的肥胖雄性和雌性糖尿病(db/db)小鼠以及瘦的非糖尿病同窝对照(db/+)中分离心脏。采用Langendorff逆行离体心脏灌注系统建立离体AHF模型:a)稳定期——在100 mmHg下用Krebs Henseleit缓冲液(含10 mM葡萄糖)灌注25分钟;b)严重急性心力衰竭(CAHF)期——在20 mmHg下用(1.2 mM棕榈酸,2.5 mM葡萄糖)灌注25分钟;c)恢复性急性心力衰竭期(RAHF)——在100 mmHg下用(1.2 mM棕榈酸,10 mM葡萄糖)灌注25分钟。治疗组在CAHF或RAHF阶段的整个相应阶段,在灌注液中加入5 μM TMZ。瘦的和肥胖的雄性在RAHF阶段接受TMZ治疗均有益。仅在瘦的组中观察到性别差异,其中发情周期阶段影响治疗效果;仅瘦的卵泡期雌性组在CAHF阶段对TMZ治疗有反应。瘦的黄体期雌性则表现出一种固有的心脏保护作用(无需治疗),但肥胖后这种作用消失。然而,在RAHF阶段开始的TMZ治疗对肥胖的黄体期雌性有益。当在RAHF阶段给药时,TMZ治疗能使雄性和肥胖雌性心脏显著恢复。瘦的和肥胖的雄性心脏之间没有差异,而瘦的雌性比瘦的雄性表现出功能恢复优势。因此,TMZ成为一个值得考虑的治疗靶点,可用于正常和肥胖糖尿病个体(男女均可)的AHF治疗,但前提是仅在恢复阶段给药,而非在非常急性的阶段给药。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b80c/5478112/c61d7decb6c7/pone.0179509.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验